We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2.
- Authors
Fang, Zhenhao; Peng, Lei; Filler, Renata; Suzuki, Kazushi; McNamara, Andrew; Lin, Qianqian; Renauer, Paul A.; Yang, Luojia; Menasche, Bridget; Sanchez, Angie; Ren, Ping; Xiong, Qiancheng; Strine, Madison; Clark, Paul; Lin, Chenxiang; Ko, Albert I.; Grubaugh, Nathan D.; Wilen, Craig B.; Chen, Sidi
- Abstract
The Omicron variant of SARS-CoV-2 recently swept the globe and showed high level of immune evasion. Here, we generate an Omicron-specific lipid nanoparticle (LNP) mRNA vaccine candidate, and test its activity in animals, both alone and as a heterologous booster to WT mRNA vaccine. Our Omicron-specific LNP-mRNA vaccine elicits strong antibody response in vaccination-naïve mice. Mice that received two-dose WT LNP-mRNA show a > 40-fold reduction in neutralization potency against Omicron than WT two weeks post boost, which further reduce to background level after 3 months. The WT or Omicron LNP-mRNA booster increases the waning antibody response of WT LNP-mRNA vaccinated mice against Omicron by 40 fold at two weeks post injection. Interestingly, the heterologous Omicron booster elicits neutralizing titers 10-20 fold higher than the homologous WT booster against Omicron variant, with comparable titers against Delta variant. All three types of vaccination, including Omicron alone, WT booster and Omicron booster, elicit broad binding antibody responses against SARS-CoV-2 WA-1, Beta, Delta variants and SARS-CoV. These data provide direct assessments of an Omicron-specific mRNA vaccination in vivo, both alone and as a heterologous booster to WT mRNA vaccine. Here the authors show that Omicron neutralizing antibody titers decline over time in mice immunized with a wild-type (WT) lipid nanoparticle (LNP)-mRNA vaccine and are robustly increased by WT or Omicron LNP-mRNA and that Omicron boosters elicit higher BA.1-neutralizing titer than WT boosters.
- Subjects
SARS-CoV-2 Omicron variant; SARS-CoV-2 Delta variant; BOOSTER vaccines; SARS-CoV-2; VACCINATION
- Publication
Nature Communications, 2022, Vol 13, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-022-30878-4